Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering
The closing of the public offering is expected to take place on or about October 3, 2023, subject to the satisfaction of customary closing conditions.
- The closing of the public offering is expected to take place on or about October 3, 2023, subject to the satisfaction of customary closing conditions.
- The gross proceeds of the offering will be approximately $4.5 million before deducting placement agent fees and other estimated offering expenses payable by the Company.
- Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as co-placement agent for the offering.
- The offering will be made only by means of a prospectus supplement and accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that Tonix may file with the SEC.